Methods for modulating kallikrein (klkb1) expression
AssigneeIsis Pharmaceuticals, Inc.
InventorsGourab Bhattacharjee, Alexey Revenko, Robert A. MacLeod
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods for decreasing kallikrein and treating or preventing inflammatory conditions in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to kallikrein include hereditary angioedema (HAE). Methods for inhibiting kallikrein can also be used as a prophylactic treatment to prevent individuals at risk for developing an inflammatory condition, such as, hereditary angioedema.
Claims33
(canceled)
A method comprising,
- identifying an animal at risk for developing an inflammatory condition;
- and
- prophylactically administering to the at risk animal a therapeutically effective amount of a modified oligonucleotide consisting of 12 to 30 linked nucleosides, wherein the modified oligonucleotide is at least 90% complementary to a kallikrein nucleic acid.
(canceled)
11-17. (canceled)
28-29. (canceled)
36-38. (canceled)
A method comprising,
- increasing or stabilizing HMWK in an animal in need thereof by administering to the animal a therapeutically effective amount of a modified oligonucleotide consisting of 12 to 30 linked nucleosides, wherein the modified oligonucleotide is at least 90% complementary to a kallikrein nucleic acid.
A method of treating an inflammatory condition in an animal in need thereof by increasing or stabilizing HMWK in the animal by administering to the animal a therapeutically effective amount of a modified oligonucleotide consisting of 12 to 30 linked nucleosides, wherein the modified oligonucleotide is at least 90% complementary to a kallikrein nucleic acid.
Dependencies are inferred from the claim text.